Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081
Greg Andrew Durm(Indiana University Health), Nasser H. Hanna(Ontario Institute for Cancer Research), Hirva Mamdani(Wayne State University), Apar Kishor Ganti(University of Nebraska Medical Center), Mary J. Fidler, Naomi Fujioka(University of Minnesota), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Shadia I. Jalal(Indiana University Health), Borys Hrinczenko(Michigan State University), Salma K. Jabbour(Rutgers, The State University of New Jersey), Sandra K. Althouse(Indiana University School of Medicine), Lawrence Feldman(University of Illinois Chicago), Ticiana Leal(University of Wisconsin Carbone Cancer Center), Jason Chesney(University of Louisville Hospital), Susan M. Perkins(Indiana University School of Medicine)
Cited by 9
Related Papers
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k